These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26703648)

  • 1. Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1.
    Carriere PP; Llopis SD; Naiki AC; Nguyen G; Phan T; Nguyen MM; Preyan LC; Yearby L; Pratt J; Burks H; Davenport IR; Nguyen TA; Parker-Lemieux K; Payton-Stewart F; Williams CC; Boué SM; Burow ME; Collins-Burow B; Hilliard A; Davidson AM; Tilghman SL
    Int J Environ Res Public Health; 2015 Dec; 13(1):ijerph13010010. PubMed ID: 26703648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness.
    Tilghman SL; Townley I; Zhong Q; Carriere PP; Zou J; Llopis SD; Preyan LC; Williams CC; Skripnikova E; Bratton MR; Zhang Q; Wang G
    Mol Cell Proteomics; 2013 Sep; 12(9):2440-55. PubMed ID: 23704778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1.
    Patel JR; Banjara B; Ohemeng A; Davidson AM; Boué SM; Burow ME; Tilghman SL
    Nutrients; 2023 Mar; 15(7):. PubMed ID: 37049472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase-Inhibitor-Resistant Breast Cancer Cells through the Induction of Apoptosis.
    Walker RR; Patel JR; Gupta A; Davidson AM; Williams CC; Payton-Stewart F; Boué SM; Burow ME; Khupse R; Tilghman SL
    Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35270029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aromatase and breast cancer.
    Brodie A; Sabnis G; Jelovac D
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.
    Sabnis G; Schayowitz A; Goloubeva O; Macedo L; Brodie A
    Cancer Res; 2009 Feb; 69(4):1416-28. PubMed ID: 19190349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis.
    Avtanski DB; Nagalingam A; Bonner MY; Arbiser JL; Saxena NK; Sharma D
    Mol Oncol; 2014 May; 8(3):565-80. PubMed ID: 24508063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammospheres of letrozole-resistant breast cancer cells enhance breast cancer aggressiveness.
    Patel JR; Gallegos KM; Walker RR; Davidson AM; Davenport I; Tilghman SL
    Oncol Lett; 2021 Aug; 22(2):620. PubMed ID: 34267813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial to mesenchymal transition is associated with rapamycin resistance.
    Holder AM; Akcakanat A; Adkins F; Evans K; Chen H; Wei C; Milton DR; Li Y; Do KA; Janku F; Meric-Bernstam F
    Oncotarget; 2015 Aug; 6(23):19500-13. PubMed ID: 25944619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy.
    Nair HB; Kirma NB; Ganapathy M; Vadlamudi RK; Tekmal RR
    Steroids; 2011 Jul; 76(8):792-6. PubMed ID: 21477609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stopping treatment can reverse acquired resistance to letrozole.
    Sabnis GJ; Macedo LF; Goloubeva O; Schayowitz A; Brodie AM
    Cancer Res; 2008 Jun; 68(12):4518-24. PubMed ID: 18559495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Long BJ; Jelovac D; Thiantanawat A; Brodie AM
    Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
    Núñez NP; Jelovac D; Macedo L; Berrigan D; Perkins SN; Hursting SD; Barrett JC; Brodie A
    Clin Cancer Res; 2004 Aug; 10(16):5375-80. PubMed ID: 15328175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glypican-3 induces a mesenchymal to epithelial transition in human breast cancer cells.
    Castillo LF; Tascón R; Lago Huvelle MR; Novack G; Llorens MC; Dos Santos AF; Shortrede J; Cabanillas AM; Bal de Kier Joffé E; Labriola L; Peters MG
    Oncotarget; 2016 Sep; 7(37):60133-60154. PubMed ID: 27507057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line.
    Ren J; Chen Y; Song H; Chen L; Wang R
    J Cell Biochem; 2013 Jun; 114(6):1395-403. PubMed ID: 23255418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 53BP1 suppresses epithelial-mesenchymal transition by downregulating ZEB1 through microRNA-200b/429 in breast cancer.
    Kong X; Ding X; Li X; Gao S; Yang Q
    Cancer Sci; 2015 Aug; 106(8):982-9. PubMed ID: 26011542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer.
    Bai WD; Ye XM; Zhang MY; Zhu HY; Xi WJ; Huang X; Zhao J; Gu B; Zheng GX; Yang AG; Jia LT
    Int J Cancer; 2014 Sep; 135(6):1356-68. PubMed ID: 24615544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-652 inhibits acidic microenvironment-induced epithelial-mesenchymal transition of pancreatic cancer cells by targeting ZEB1.
    Deng S; Li X; Niu Y; Zhu S; Jin Y; Deng S; Chen J; Liu Y; He C; Yin T; Yang Z; Tao J; Xiong J; Wu H; Wang C; Zhao G
    Oncotarget; 2015 Nov; 6(37):39661-75. PubMed ID: 26498682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of down-regulated transcriptional repressor ZEB1 on the epithelial-mesenchymal transition of ovarian cancer cells.
    Chen D; Wang J; Zhang Y; Chen J; Yang C; Cao W; Zhang H; Liu Y; Dou J
    Int J Gynecol Cancer; 2013 Oct; 23(8):1357-66. PubMed ID: 24257549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
    Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.